Is Nivolumab Dosed by Weight?
Nivolumab (Opdivo) uses fixed dosing for most indications, not weight-based adjustments. Adults receive 240 mg every 2 weeks or 480 mg every 4 weeks intravenously, regardless of body weight.[1][2] This shifted from earlier weight-based regimens (3 mg/kg every 2 weeks) after trials showed fixed doses provide similar efficacy and safety across weights from 40-120 kg.[3]
Why the Switch from Weight-Based Dosing?
Fixed dosing simplifies administration and reduces errors. Phase 3 trials like CheckMate 067 (melanoma) and CheckMate 017/057 (lung cancer) confirmed fixed 240/480 mg doses match exposure of 3 mg/kg, with no need for adjustments in obesity or underweight patients.[3][4] FDA approved this in 2018 based on pharmacokinetic modeling and clinical data.[2]
Adjustments for Special Populations?
No routine weight-based changes, but dose modifications apply for toxicity:
- Withhold for grade 2 immune-related adverse events; resume at same dose when resolved.
- Permanently discontinue for grade 3-4 events or recurrent grade 2.[1]
Pediatric dosing (≥40 kg) is weight-based at 3 mg/kg every 2 weeks for some cancers, but adults stay fixed.[1] Renal/hepatic impairment rarely requires changes unless severe.[2]
What About Obese or Underweight Patients?
Fixed dosing works across BMI ranges. PK studies show no clinically meaningful differences in exposure for patients >120 kg or <40 kg, avoiding under- or overdosing risks.[3][5] Real-world data supports this, with consistent outcomes in diverse weights.[4]
How Does This Compare to Other Checkpoint Inhibitors?
| Drug | Adult Dosing | Weight-Based? |
|------|--------------|---------------|
| Nivolumab | 240 mg Q2W or 480 mg Q4W | No (fixed) |
| Pembrolizumab | 200 mg Q3W or 400 mg Q6W | No (fixed) |
| Ipilimumab | 1 mg/kg Q3W (induction) | Yes |
| Atezolizumab | 1200 mg Q3W | No (fixed) |
Nivolumab aligns with pembrolizumab and atezolizumab trends toward fixed doses for convenience.[2][6]
[1]: [Nivolumab Prescribing Information (FDA, 2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf)
[2]: Opdivo HCP Dosing Guide (BMS)
[3]: CheckMate 067 PK Analysis, J Clin Oncol (2018)
[4]: FDA Approval Summary for Fixed-Dose Nivolumab (2018)
[5]: Nivolumab PK in Obesity, Clin Cancer Res (2020)
[6]: Pembrolizumab Prescribing Information (FDA, 2023)